Quantcast

Latest Biologic Stories

2014-02-06 00:22:38

NORTH CHICAGO, Ill., Feb. 5, 2014 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) announces a US$320 million [approximately S$400 million] investment to establish operations in Singapore for small molecule and biologics active drug substance manufacturing. The completed facility will provide manufacturing capacity for emerging compounds within AbbVie's oncology and immunology pipeline to serve markets globally. The investment will establish the first manufacturing presence in Asia by...

2014-02-05 20:23:53

DUBLIN, February 5, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/9lglrg/biologics_and) has announced the addition of the "Biologics and Biosimilars World Markets" [http://www.researchandmarkets.com/research/9lglrg/biologics_and ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Biologics are complex molecules manufactured through cell culture recombinant DNA technology. Biologics...

2014-02-05 16:26:30

DUBLIN, February 5, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/37b52b/bioseparation) has announced the addition of the "Concise Analysis of the Bioseparation Systems for Global Biopharmaceutical Markets" [http://www.researchandmarkets.com/research/37b52b/bioseparation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) 'Concise Analysis of the Bioseparation Systems for Global...

2014-02-05 12:27:53

Portable cold chain logistics allows longer shelf life for live tissue cells PHILADELPHIA and LAKE FOREST, Calif., Feb. 5, 2014 /PRNewswire/ -- Liventa Bioscience (formerly AFcell Medical) and Cryoport, Inc. (OTC:CYRX) today announced a major strategic alliance aimed at serving the many points of orthopedic care delivery with Liventa's cell-based, advanced biologics tissue forms. The exclusive agreement combines Cryoport's proprietary, purpose-built cold chain logistics solutions...

2014-02-04 08:34:03

WASHINGTON, Feb. 4, 2014 /PRNewswire-USNewswire/ -- In advance of today's Federal Trade Commission (FTC) meeting, "Follow-On Biologics Workshop: Impact of Recent Legislative and Regulatory Naming Proposals on Competition," health advocacy organizations from across the country jointly submitted a letter to FTC Commissioner Edith Ramirez, urging the Commission to give patient safety and consumer protection the important weight and priority they deserve. The Alliance for Patient...

2014-02-04 08:33:11

ROCKVILLE, Md., Feb. 4, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the BIO CEO & Investor Conference on Monday, February 10, 2014, at 10:00 a.m. (ET) at the Waldorf Astoria (Duke of Windsor room) in New York. A live webcast of Synthetic Biologics' presentation may be accessed by...

2014-02-03 12:27:27

LONDON, Feb. 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Biologics and Biosimilars World Markets Biologics are complex molecules manufactured through cell culture recombinant DNA technology. Biologics additionally comprise recombinant insulin, growth hormone and monoclonal antibodies for treating conditions such as cancer and autoimmunity. Also known as follow-on biologics or subsequent entry biologics (SEBs), biosimilars are to biologics...

2014-02-03 00:21:09

Availability of 150 mg formulation increases dosing convenience and flexibility MUMBAI and PITTSBURGH, Feb. 3, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched the world's first trastuzumab biosimilar in India. The product, which will be marketed by Mylan under the brand name Hertraz(TM), is a biosimilar to Roche's...

2014-01-31 23:24:50

The Biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. (PRWEB) January 31, 2014 The “Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018”, provides a detailed overview of the major...

2014-01-30 23:23:35

Fundamentals of Canadian Regulatory Affairs, Fourth Edition reflects the changes in technology in the three years since the previous edition was published in 2011, and examines their impact on regulations. Rockville, MD, USA (PRWEB) January 30, 2014 The Regulatory Affairs Professionals Society (RAPS) has updated its essential reference text, Fundamentals of Canadian Regulatory Affairs, the only book of its kind extensively covering the regulation of healthcare products marketed in Canada....


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related